FDA 2026年新药清单新增 Hovilpri 10月9日获批用于难治性疱疹病变
美国食品药品监督管理局（FDA）公布的2026年新药批准清单显示，Hovilpri（活性成分 pritelivir）已于10月9日获批。该药获批用途为治疗免疫功能减弱、且对其他疗法未产生反应的成人，其由单纯疱疹病毒引起的皮肤黏膜病变。
该批准被列入 FDA 2026 年新型药物疗法清单。GSM 仅作药品监管新闻报道，具体用药适应症与使用方式以 FDA 标签和医生判断为准。（资料来源：美国食品药品监督管理局 FDA，2026年新药批准清单）
FDA Lists Hovilpri Among 2026 Novel Drug Approvals With Oct. 9 Approval
The U.S. Food and Drug Administration's 2026 novel drug approvals list shows Hovilpri, with the active ingredient pritelivir, was approved on Oct. 9. Its approved use is to treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies.
The approval appears in FDA's 2026 list of novel drug therapy approvals. GSM is reporting this as regulatory news; prescribing decisions remain subject to the FDA label and a clinician's judgment. (Source: U.S. Food and Drug Administration, Novel Drug Approvals for 2026)
图片来源：Wikimedia Commons · FDA Unit Mobilizes for Emergency Response - Emergency Operations Center (EOC) (6992808772).jpg · Public domain